Prematurity and Genetic Liability for Autism Spectrum Disorder

Yali Zhang[1,2], Ashraf Yahia[1,2], Sven Sandin[3,4,5], Ulrika Åden[6,7,8] and Kristiina Tammimies[1,2*]

[1]Center of Neurodevelopmental Disorders (KIND), Centre for Psychiatry Research, Department of Women's and Children's Health, Karolinska Institutet
[2]Astrid Lindgren Children's Hospital, Karolinska University Hospital, Region Stockholm, Stockholm, Sweden
[3]Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
[4]Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, USA
[5]Seaver Center for Research and Treatment at Mount Sinai, New York, USA
[6]Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
[7]Department of Neonatology, Division of Neonatal Medicine, Karolinska University Hospital, Stockholm, Sweden
[8]Department of Bioclinical sciences, Linköping University, Linköping, Sweden

Abstract

Background: Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by diverse presentations and a strong genetic component. Environmental factors, such as prematurity, have also been linked to increased liability for ASD, though the interaction between genetic predisposition and prematurity remains unclear. This study aims to investigate the impact of genetic liability and preterm birth on ASD conditions.

Methods: We analyzed phenotype and genetic data from two large ASD cohorts, the Simons Foundation Powering Autism Research for Knowledge (SPARK) and Simons Simplex Collection (SSC), encompassing 78,559 individuals for phenotype analysis, 12,519 individuals with genome sequencing data, and 8,104 individuals with exome sequencing data. Statistical significance of differences in clinical measures were evaluated between individuals with different ASD and preterm status. We assessed the rare variants burden using generalized estimating equations (GEE) models and polygenic load using ASD-associated polygenic risk score (PRS). Furthermore, we developed a

machine learning model to predict ASD in preterm children using phenotype and genetic features

available at birth.

Results: Individuals with both preterm birth and ASD exhibit more severe phenotypic outcomes

despite similar levels of genetic liability for ASD across the term and preterm groups. Notable,

preterm ASD individuals showed an elevated rate of de novo variants identified in exome sequencing

(GEE model with Poisson family, p-value = 0.005) in comparison to the non-ASD preterm group.

Additionally, a GEE model showed that a higher ASD PRS, preterm birth, and male sex were

positively associated with a higher predicted probability for ASD, reaching a probability close to 90%.

Lastly, we developed a machine learning model using phenotype and genetic features available at

birth with limited predictive power (AUROC = 0.65).

Conclusions: Preterm birth may exacerbate the multimorbidity present in ASD, which was not due to

the ASD genetic factors. However, increased genetic factors may elevate the likelihood of a preterm

child being diagnosed with ASD. Additionally, a polygenic load of ASD-associated variants had an

additive role with preterm birth in the predicted probability for ASD, especially for boys. We propose

that incorporating genetic assessment into neonatal care could benefit early ASD identification and

intervention for preterm infants.

Keywords: Prematurity, Autism Spectrum Disorder, Genetics, Polygenic risk score, Machine learning,

Generalized estimating equations model.

Introduction

Autism Spectrum Disorder (ASD) is an early-onset neurodevelopmental condition characterized by

challenges in social interaction, communication, and restrictive and repetitive behaviors and interests

[1]. In addition to these core symptoms, individuals with ASD have multiple co-occurring

neurodevelopmental, psychiatric, and physical conditions, which contribute to clinical heterogeneity

[2].

The etiology of ASD is multifaceted and not yet fully elucidated [3,4]. However, genetic factors

account for up to 80-90% of the liability for ASD [4–6]. Rare de novo variants (DNV), especially those

affecting the gene function of constraint genes, are shown to be enriched in ASD [7,8]. Rare inherited

variants in ASD-related genes are also shown to be overtransmitted from parents to their children

with ASD [5,9]. In addition to rare variants, genome-wide association studies (GWAS) have identified

a few common variants associated with ASD, and the polygenic load calculated using polygenic risk

score (PRS) has demonstrated predictive ability for ASD and ASD traits [10,11]. Furthermore, ASD PRS

can uniquely predict variability in cognitive performance [11].

In addition to genetic factors, there are several environmental factors associated with ASD [3]. The

most robustly associated environmental stressor is prematurity, with ASD likelihood in preterm about

two to four folds higher than in term, and ASD likelihood increasing as gestational age at birth

decreases [12,13]. Although preterm birth involves both genetic and environmental components

[14], it is typically discussed as an environmental factor in ASD studies [3,15]. Preterm birth, defined

as delivery with gestational age before 37 weeks, can be further categorized into four preterm sub-

categories: extremely preterm (<28 weeks), very preterm (28-31 weeks), moderate preterm (32-33

weeks), and late preterm (34-36 weeks). Prematurity is not only associated with ASD but also with

neurocognitive development and other health outcomes [16–18]. Earlier studies investigating

phenotypes in children with ASD suggested that extremely or very preterm ASD children have more

language deficits and developmental delays compared to term ASD children [19,20]. However, others

reported that no significant differences in development were found when studying the entire

preterm group [21]. Moreover, preterm birth as an exposure is associated with various comorbidities

in ASD, including attention and behavioral problems, neurological disorders, and growth deficiency.

However, more investigations are needed to understand ASD phenotypic spectrum in preterm and

term birth as well as how different sub-groups of prematurity contribute to specific medical

outcomes and traits.

Interestingly, preterm infants have been found to have increased DNV rates compared to term [22],

and various de novo CNVs in preterm were found related to neurodevelopmental disorders genes

(NDD genes) [23], but it remains uncertain whether DNV burden is further elevated when both ASD

and preterm birth are present. Moreover, the relationship between ASD polygenic load and

prematurity has only been evaluated by Cullen et al based on cognition, but no interaction was found

between ASD PRS and gestational age at birth [15]. Furthermore, there are indications that a small

fraction of preterm individuals would have recognizable genetic disorders [24]. However, there have

not been specific studies focusing on genetic factors within preterm individuals and ASD.

While genetic and phenotypic studies on the population level are informative, these analyses may

miss interactions and non-linear relationships within or between factors on an individual level. To

address this complexity, machine learning (ML) has the potential to identify patterns in high-

dimensional data that traditional statistical methods may overlook, aiding in prediction. To date, ML

prediction models have emerged to predict ASD using different data sources, such as routine medical

assessments and electronic records [25,26], genetic data [27], and integrative models [28]. However,

none of the published ML models currently predict ASD in preterm children. In the existing ML

models for ASD prediction, included features are typically collected when the child is at least 1-2

years of age or older [25,29]. It remains unclear whether integrating phenotype and genetic

information available at birth could enable earlier ASD identification in preterm infants.

In this study, we aimed to enhance our understanding of ASD in preterm children by analyzing both

clinical and genetic data in two large ASD cohorts, the Simons Foundation Powering Autism Research

for Knowledge (SPARK) [8,30], and the Simons Simplex Collection (SSC) [31]. Across individuals with

different ASD and prematurity sub-groups, we first examined their phenotype severity through the

prevalence and multimorbidity of other medical diagnoses. Thereafter, we assessed the burden of

rare and common sequence-level variants. Finally, we built an ML model using both phenotype and

genetic features that could be obtained at birth to predict ASD in preterm individuals.

Methods

Study cohorts

The Simons Foundation Powering Autism Research for Knowledge (SPARK) database, initiated by the

Simons Foundation Autism Research Initiative (SFARI), recruited families in the USA with one or

more children diagnosed with autism spectrum disorder (ASD) [30]. We utilized demographic and

phenotype data from the SPARK collection version 9 with a release date 2022-12-12. We considered

medical and psychiatric diagnosis history from the basic medical screen dataset, grouping specific

diagnoses into nine diagnostic categories: behavior, development, mood, growth, birth, eating

habits (Eat), neurological conditions (Neuro), visual and auditory impairments (Visaud), and sleep.

This dataset includes 9196 individuals with ASD and born preterm with gestational age less than 36

weeks (ASD-preterm), 65021 individuals with ASD and born term (ASD-term), and 2706 individuals

without ASD and born preterm (non-ASD-preterm). We also stratified preterm individuals into four

sub-groups based on gestational age: extremely preterm (<28 weeks), very preterm (28-31 weeks),

moderate preterm (32-33 weeks), and late preterm (34-36 weeks). Additionally, we compared

quantitative measures using the Child Behavior Checklist (CBCL) t-score for 1 to 5 and 6 to 18 years

of age, Developmental Coordination Disorder Questionnaire (DCDQ) final score, Repetitive Behavior

Scale-Revised (RBS-R) total final score, Social Communication Questionnaire (SCQ) final score and

Full-Scale Intelligence quotient (FSIQ) score. Additional file 1: Tables S1 and S2 provide detailed

specific diagnoses and quantitative measures descriptions.

For the genetic part, variant calling dataset SPARK genome sequencing (GS) version 1.1 was used,

including 12519 individuals from 3394 families, with 315 ASD-preterm, 2788 ASD-term, and 155 non-

ASD-preterm individuals. We also utilized earlier published DNV data from exome sequencing (ES) to

calculate the event rate [8]. Among the 6444 ASD individuals with DNV information, 5747 were born

full-term, and 697 were born preterm. Furthermore, DNV information was accessible for 210

preterm children without ASD.

We also used the Simons Simplex Collection (SSC) cohort. SSC recruited more than 10,000 individuals

from 2,000 families [31]. Due to the absence of preterm information for non-ASD individuals

(siblings of ASD probands), we only conducted studies for ASD-preterm and ASD-term groups. After

excluding individuals with unreliable gestational age, unknown ASD diagnosis, births occurring post-

term (gestational age > 40 weeks), and missing outcomes information, we retained 1,637 probands

diagnosed with ASD (157 preterm and 1479 term) for the diagnostic category analysis. Additionally,

we analyzed available quantitative measures, including CBCL score, DCDQ score, SCQ score, and IQ

score. Detailed descriptions of specific diagnoses and qualitative measures are provided in

Additional file 1: Tables S3 and S4. We incorporated the de novo variants (DNV) dataset from Ng et

al in our analysis, encompassing 1450 ASD individuals after excluding post-term births [32].

Additionally, the Polygenic Risk Score (PRS) dataset we used sourced from Weiner et al comprised

1590 ASD individuals, excluding post-term births [33].

 De novo variant calling and analysis

In SPARK, GS was conducted on the Illumina NovaSeq 6000 system. Variant calling was performed

using GATK (version 3.5) with HaplotypeCaller, and all samples were jointly called by GLnexus

(version 1.4.1). To find de novo variants (DNV) of children, we included all trios. For families with

more than one child, each child forms a trio with their parents, resulting in multiple trios within the

same family. There were 5,712 trios from 3,364 families. We used two tools to call the DNV from

SPARK trios, and true DNV was selected when it was found in both tools. The DNV was called if it was

labeled as "denovo" with allele balance (AB) in children higher than 0.25 in Slivar (version 0.2.8) and

identified as high confidence DNV in GATK (version 4.1.4.1) [34,35]. For pseudo-autosomal regions

on the sex chromosome, we separately considered the variant genotype as 1/0 in children. We did

not find DNVs on chrY in pseudo-autosomal regions. Then, we did quality control to further filter the

DNV by removing variants with GQ<20, DP<10, gnomAD population allele frequencies > 0.001, and

variants of either 10 A's or T's in a row. We filtered out DNVs on genomic centromeres and low

complex regions. Then we removed DNV if 1) it can be found in other family's parents, 2) it can be

found in only children but more than three families, and 3) it on positions having more than 3 multi-

alleles. We identified 432,903 DNVs, including 16,155 exonic DNVs and 986 loss-of-function (LOF)

variants. We filtered out 29 children with DNV counts beyond three times the standard deviation

from the mean DNV count. Based on these criteria, the average number of rare DNVs per child was

75.9.

We annotated DNVs by ANNOVAR and SnpEff [36,37]. DNVs with Sequence Ontology (SO) terms as

"frameshift", "splice_acceptor", "splice_donor", "start_lost", "stop_gained", and "stop_lost" in gene

effect were considered as LOF DNV. Additionally, we identified variants on the neurodevelopmental

disorder-related genes (NDD gene) using high-confidence ASD genes collected by the Simons

Foundation Autism Research Initiative (SFARI) (2024-01-16 release) with gene scores of 1 or 2 and

181 labeled as syndromic and green gene list of Intellectual disability - microarray and sequencing

182 (Version 5.497) on Genomics England PanelApp (2024-03-14 accessed) [38,39].

184 Inherited variants calling

186 We extracted variants on the genomic protein coding NDD genes (as the NDD gene list we used for

187 DNV analysis) using VCFtools/0.1.16 [40]. Then we annotated the inheritance mode of NDD genes

188 using the ID gene panel app, SysNDD database (v0.1.0) and DDgenes [39,41,42]. There were 80%

189 (1625 genes) of NDD genes annotated, including 738 dominant genes coded as monoallelic or

190 dominant, and 944 recessive genes coded as biallelic or recessive in databases. To restrict the

191 analysis to rare inherited variants, we used the allele frequency filter threshold of 0.001 and 0.01 for

192 dominant and recessive genes, respectively. Variants with GQ<20, DP<10, and genotypes conflicting

193 with the inheritance mode of located genes were filtered out. We did not find compound variants

194 (more than one heterozygous variant on the same recessive gene for one child). For variants on

195 dominant genes, we identified LOF following the same process in the DNV part and found damage

196 missenses variants met at least one of the following conditions: CADD>=20, SIFT labeled as D,

197 POLYPHEN labeled as P and D, PHYLOP>=2.0 or REVEL>=0.5. From 5,712 trios in the SPARK GS

198 database, we identified 245,671 and 4,346 inherited variants in dominant and recessive NDD genes,

199 respectively. We identified 2,717 LOF and 39,136 damaging missense variants in genes with a

200 dominant inheritance mode.

202 Polygenic risk score

204 Based on GS jointly called variants from 12,519 SPARK participants, we performed quality control for

205 individuals and variants using PLINK1.9 with parameters listed in Additional file 1: Table S5, retaining

11,933 individuals and 9,558,997 variants with a total genotyping rate of 99.9% [43]. Then, genome

coordinates of variants were converted from hg38 to hg19 using liftOver (Version 2017-03-14) [44],

and 9,428,216 were mapped after removing duplicated variants. We calculated the posterior SNP

effect size estimates using PRS-CS with ASD GWAS summary statistics from the Psychiatric Genomics

Consortium (November 2017 release) (46351 individuals) and European LD reference data from

1000 Genome phase III [10,45]. The default parameters used in PRS-CS also be listed in Additional

file 1: Table S5. The final PRS was calculated using the score function in PLINK1.9 with the estimated

posterior SNP effect size. To minimize the effects on different populations, we analyzed the ancestry

of individuals using Principal component analysis (PCA) by pca command in PLINK1.9. The ten

principal components (PC1-10) were included as covariates when we calculated the association

between phenotype and PRS.

Statistical analysis

All analyses were performed using R programming language (version 4.2.2). Commencing with an

exploration of phenotypes, we investigated two pairs of groups: preterm and term birth within

individuals diagnosed with ASD (ASD-preterm versus ASD-term); and individuals diagnosed with ASD

to those without ASD within preterm birth (ASD-preterm versus non-ASD-preterm). An individual

was considered to possess the diagnosis feature if any specific diagnosis within that diagnostic

category was exhibited, no matter how many specific diagnoses there were at the same time.

In phenotypic analysis, the prevalence is reported by the frequency of individuals with the diagnosis.

We examined the differences in prevalence between ASD-preterm and ASD-term, ASD-preterm and

non-ASD-preterm using odds ratios with 95% confidence interval (CI) and statistical significance

reported by FDR-adjusted p-values in χ^2 test. After stratifying preterm stages, we used χ^2 test to

evaluate differences across preterm stages, post-hoc comparisons for each pair of preterm stages,

and Kendall's tau test to examine rank correlation of preterm stages with prevalences. Then,

prevalences of multimorbidity (one, two, three, four, or not less than five diagnoses) were estimated

by ASD and preterm status, and differences were examined by χ^2. Additionally, we examined

difference of quantitative measures in pairwise using the 2-sided Wilcoxon rank sum test and in

multiple comparisons using the Kruskal Wallis rank sum test. To account for multiple testing, we

applied false discovery rate correction to p-values.

The burden of DNV and inherited variants was evaluated by comparing rates of such variants in each

subgroup categorized by ASD and preterm status. We assessed the statistical differences between

groups through a generalized estimating equation (GEE) model with Poisson family and sex as a

covariate. GEE model is more robust to assumptions of data following a particular data distribution

and adjusts for correlations between individuals, e.g. siblings and families [46]. PRSs were z-

standardized and statistical significance for PRS distribution was reported by the 2-sided Wilcoxon

rank sum test. The association between targeted phenotype (y/n) and PRS in each subgroup was also

evaluated in GEE logistic model with sex(m/f) and PC1-10 from ancestry checking as covariates.

To examine the associations between ASD diagnosis and possible variables, we modeled the

probability of ASD (y/n) by fitting GEE logistic model(s) with the equation as [ASD (y/n) ~ sex (m/f) +

preterm (y/n) + standardized PRS] in European population to find the correlation between ASD

diagnosis and possible variables. To visualize the predicted probabilities of ASD from the GEE logistic

model, we utilized ggemmeans function in ggeffects R package (version 1.5.1) [47], showing the

average predicted probabilities of the ASD for specific levels of variables adjusted for other

covariates in the model. After that, the variable (preterm (y/n) * standardized PRS) was added to the

GEE logistic model to check the correlation between ASD (y/n) and the interaction of preterm status

and PRS. To detect the association between multimorbidity and DNV burden, GEE models (Table S4)

and linear regression were used.

Machine learning model

This part of the analysis was performed in R (version 4.2.2). Within preterm individuals, we utilized non-ASD and ASD diagnoses as two classification flags, incorporating features obtained from data that can be collected at birth. For phenotypical variables, we included birth complications, sex, and birth-related conditions. Genetic variables encompassed the count of several types of genetic variants, the CADD score of de novo variants (DNV), and the PRS of ASD. To remove redundant variables and identify informative features, we employed the Recursive Feature Elimination (RFE) algorithm [48]. RFE is a feature selection technique that iteratively removes the least important features based on model performance, refitting the model with the remaining features until the optimal subset of features is identified. In RFE, we utilized random forest function and 10-fold cross-validation in the underlying model to assess feature importance throughout the process. For the features selected after RFE, we only retained the more general feature (e.g., retaining LOF over LOF on NDD genes) in any pair of features with a correlation coefficient above 0.7 to reduce multicollinearity. The details of selected features are listed in Additional file 1: Table S6.

We applied R package caret (version 6.0-94) [49] to train the ML models. Given the limited sample size and the higher proportion of ASD samples than non-ASD, we conducted nested cross-validation (NCV) and hyperparameter tuning with grid search to enhance model performance. In NCV, we partitioned the data into 10 folds in the outer loop, with nine folds used for training and the remaining fold for testing. Within the inner loop, we performed repeated 5*5-fold cross-validation, and the model with the best performance was applied to the outer loop. We employed three algorithms—Extreme Gradient Boosting (XGBoost), Random Forest (RF), and Linear Support Vector Machine (SVM)—to construct the models. The values of hyperparameter tuning for each model are detailed in Additional file 1: Table S7. We reported evaluation metrics, including accuracy with a 95% CI, area under the receiver operating characteristic curve (AUROC), specificity, sensitivity, and F1-

score. Moreover, the SHapley Additive exPlanations (SHAP) values for features were computed and

visualized using the R package SHAPforxgboost (version 0.1.3) [50], quantifying the contribution of

each feature to individual model predictions in terms of direction and magnitude.

Result

Phenotype comparison across ASD and prematurity

We utilized basic medical screening data from 181,248 individuals in the SPARK version 9 cohort

(release date 2022-12-12). Among them, 74,217 (41%) were diagnosed with ASD, and 11,902 (7%)

were born preterm. When performing phenotype comparison, we grouped individuals with 9,196

individuals with ASD and being preterm (ASD-preterm), 65,021 individuals with ASD but being term

(ASD-term), and 2,706 preterm individuals without ASD diagnosis (non-ASD-preterm) (Figure 1, Table

1). In the SSC cohort, gestational age records were available only for probands with ASD, of which

157 were preterm and 1,479 were term. We stratified the preterm stage based on gestational age at

birth (Table 1).

Figure 1. Overview design of the study. Firstly, we performed phenotype analysis on diagnosis

prevalence, burden of multimorbidity and quantitative measures in the SPARK cohort. The sample

size of SPARK is shown in the Venn diagram, with blue indicating ASD, pink indicating preterm with

unknown gestational age, and green indicating preterm with known gestational age. Secondly, we

analyzed the de novo variant and inherited variant burden, separately, focusing on loss-of-function

variants and damaging missense and if these affected neurodevelopmental disorder (NDD) genes.

Additionally, we utilized polygenic risk scores for common variants associated with ASD. For

validation, we applied similar analyses in the SSC cohort. Thirdly, we integrated phenotype and

genomic data to train the machine learning models with different algorithms to predict ASD

diagnosis in the preterm group. Shapley additive explanations (SHAP) values assess the effect of each

feature on the model performance.

Table 1. Characteristics of the analyzed samples.

	Cohort	SPARK (version 9)		SSC
		ASD	**Non-ASD**	**ASD**
Phenotype analysis	Number of samples	74217	/	1636
	Preterm	9196	2706	157
	Extremely preterm (GA <28 weeks)	699 (8%)	109 (4%)	/
	Very preterm (GA 28-31weeks)	987 (11%)	274 (10%)	2 (1%)
	Moderate preterm (GA 21-33 weeks)	1274 (14%)	372 (14%)	11 (7%)
	Late preterm (GA 34-36 weeks)	5659 (62%)	1754 (65%)	144 (92%)

		Unknown GA	577 (6%)	197 (7%)	/
		Male:Female	6860:2336	1358:1348	139:18
		Term	65021	/	1479
		Male:Female	48069:16952	/	1270:209
Genetic analysis	De novo variant (WGS)	Preterm	309	164	/
		Male:Female	257:52	90:74	/
		Term	2728	/	/
		Male:Female	2172:556	/	/
	De novo variant (WES)	Preterm	697	210	137
		Male:Female	563:134	119:91	121:16
		Term	5747	/	1313
		Male:Female	4557:1190	/	1129:184
	Inherited variant	Preterm	310	165	/
		Male:Female	258:52	90:75	/
		Term	2742	/	/
		Male:Female	2182:560	/	/
	PRS	Preterm	305	161	155
		Male:Female	252:53	86:75	137:18
		Term	2702	6472	1435
		Male:Female	2134:568	2817:3655	1236:199
Machine learning		Preterm	279	150	/
		Male:Female	230:49	81:69	/

/ Mark as data were not analyzed. GA = Gestational age at birth.

We performed analysis on nine available diagnostic categories recorded in the basic medical

screening dataset in SPARK phenotype database version 9, involving behavior, development, mood,

growth, birth, eating habits (eat), neurological conditions (neuro), visual and auditory impairments

(visual), and sleep (details of diagnostic categories are described in Additional file 1: Table S1). For

each category, we assigned a binary variable indicating the presence or absence of conditions within

that category, rather than counting the number of specific diagnoses. The prevalence of all diagnostic

categories analyzed was higher in ASD-preterm compared to ASD-term (Figure 2A). Specifically, ASD-

preterm had higher odds ratio (OR) for all diagnostic categories, with the highest being for birth and

growth diagnoses (OR=2.18 and 2.18, χ^2 tests with False Discovery Rate [FDR]-adjusted p-

value=5.6×10^{-55} and 9.2×10^{-158}, respectively). Additionally, preterm birth was associated with a

modestly increased likelihood of other behavioral diagnoses compared to term in the ASD group

(OR=1.2, p-value=5×10^{-15}). We also observed significantly different prevalences of diagnostic

categories (χ^2 test with FDR-adjusted p value < 0.001 for all categories) when we considered different

sub-groups of preterm birth (Additional file 1: Figure S1A). Furthermore, we identified linear trends

across different preterm stages, with groups of lower gestational age showing a higher prevalence in

growth, eating, neuro, and visual diagnostic categories (Kendall's tau test, FDR-adjusted p-

value=0.04). Almost all the preterm sub-groups had a higher prevalence of diagnostic categories

compared to the term stage (FDR-adjusted p-values of the post-hoc comparisons of χ^2 test are in

Additional file 1: Table S8)

Then, we analyzed multimorbidity, indicated as the number of concurrent diagnoses among the ASD

individuals, revealing that ASD-preterm exhibited a higher likelihood of the higher number of

concurrent morbidities compared to ASD-term (Figure 2B, χ^2 test with p-value<2.2×10^{-16}). In ASD,

preterm sub-groups showed differences in the burden of multimorbidity (Additional file 1: Figure

S1B, χ^2 test with p-value<2.2×10^{-16}), in which extremely and moderate preterm subgroups exhibited a

significantly higher burden of multimorbidity with >=5 diagnoses compared to late preterm

(Additional file 1: Table S9, post-hoc test of χ^2 test with FDR-adjusted p-values=1.6×10^{-5}, 0.02

respectively). For diagnostic categories with more than two specific diagnoses, we found a positive

linear correlation between the number of specific diagnoses, i.e., multimorbidity, and the odds ratio

of preterm versus term, except for birth-related issues (Additional file 1: Figure S1C). This indicated

that preterm ASD individuals tend to have more specific diagnoses within categories as well as across

categories than term ASD individuals.

Next, we analyzed quantitative measures for overall behavioral challenges and specific symptom

domains. We observed significant differences between ASD-preterm and ASD-term (2-sided

Wilcoxon rank sum test with FDR adjustment), although the large sample size may amplify the

differences (Figure 2C). ASD-preterm had increased severity of behavioral challenges (CBCL score for

1-5y, p-value=$1.4×10^{-3}$; for 6-18y, p-value=0.0043), developmental coordination disorder (DCDQ final

score, p-value=$2.5×10^{-21}$), repetitive behaviors (RBS-R score, p-value=$6.7×10^{-34}$), and social

communication skills (SCQ score, p-value=$1.4×10^{-20}$), as well as lower IQ scores (p-value=0.02).

Comparing different sub-groups of preterm birth, we found that extremely preterm has the lowest

DCDQ final score compared to other stages (2-sided Wilcoxon rank sum test, FDR-adjusted p-values

are 0.003, 0.002, and $2.7×10^{-5}$ when compared to very preterm, moderate preterm, and late

preterm, respectively) (Additional file 1: Figure S2).

Figure 2. The phenotype comparison between preterm and term with ASD in the SPARK version 9
cohort. Color bars are the same across three panels and shown at the top of panel B. A. Prevalence
and odds ratio with 95% confidence interval (CI) of diagnosis. The exact prevalence values are labeled
on the top of the bars. ORs are given among ASD individuals born preterm vs term. B. Distribution of
the number of multimorbidity. C. Differences in Child Behavior Checklist (CBCL) t-score for 1 to 5 and
6 to 18 years of age, Developmental Coordination Disorder Questionnaire (DCDQ), Repetitive
Behavior Scale-Revised (RBS-R) score, Social Communication Questionnaire (SCQ) and Full-Scale IQ
(Fsiq) among ASD individuals born preterm and term. Significance was assessed using the 2-sided

Wilcoxon rank sum test with the FDR-adjusted p-value marked in the plots as 0-0.001***, 0.001-
0.01**, 0.01-0.05* or NS (non-significant difference).

To complement our analyses within the ASD individuals, we analyzed if there were any differences

within preterm birth for the same phenotype measures. The ASD-preterm had more severe

outcomes in comparison to non-ASD-preterm with increased severity with lower gestational age

(Additional file 1: Figure S3A-B, S4). The developmental diagnostic category had the highest

prevalence (72%) in the ASD group resulting in 8.8 OR (95% CI 7.9-9.7) when compared to non-ASD.

For quantitative measures, the ASD group had statistically significantly higher SCQ final scores

compared to the non-ASD group (2-sided Wilcoxon rank sum test, p-value$<2.2\times10^{-16}$) (Additional file

1: Figure S3C).

ASD-preterm and term comparisons within the SSC cohort also showed a statistically significantly

higher prevalence of eating problems (χ^2 test with FDR-adjusted p-value$=1.4\times10^{-6}$) and a similar trend

towards having more multimorbidity compared to ASD-term (Additional file 1: Figure S5A-B, χ^2 test p-

value=0.045). No statistically significant differences were observed in the quantitative measures

(Additional file 1: Figure S5C).

Genetic variants comparison across ASD and prematurity

To investigate the burden of de novo variants, we analyzed available genome sequencing (GS) and

exome sequencing (ES) data from SPARK and SSC. The population analyzed for GS included 310 ASD-

preterm, 2,742 ASD-term, and 165 non-ASD-preterm individuals. The ES dataset contained 697 ASD-

preterm, 5,747 ASD-term, and 210 non-ASD-preterm individuals. We did not observe any significant

difference in DNV event rate or distribution of DNV numbers between ASD-preterm and ASD-term

(Figure 3A, Additional file 1: Figure S6A), or between ASD-preterm and non-ASD-preterm derived

from GS (Figure 3D, Additional file 1: Figure S6B), even when analyzing only the exonic region

(Additional file 1: Figure S7A-B). Similarly, no statistically significant differences were found

comparing de novo burden from GS in 137 ASD-preterm and 1313 ASD-term in the SSC (Additional

file 1: Figure S7C).

When analyzing DNV event rates obtained from ES data [8] from SPARK, no statistically significant

differences were found between ASD-preterm and ASD-term (Figure 3B, Additional file 1: Figure

S6C). However, ASD-preterm individuals had more exonic DNVs (p-value=0.005), exonic DNVs on NDD

genes (p-value=0.024), and LOF affecting NDD genes (p-value=0.018) than non-ASD-preterm (Figure

3E, Additional file 1: Figure S6D). We stratified the ASD-preterm and non-ASD-preterm by gestational

age preterm subgroups and observed a similar trend in both the moderate and late preterm groups.

However, due to the limited sample size, a statistically significant difference between ASD-preterm

and non-ASD-preterm was only detected in the event rate of DNVs in NDD genes in the moderate

preterm group (p-value=0.02) and in both overall DNV and DNV in NDD genes in the late preterm

group (p-value=0.002 and 0.04 respectively). Interestingly, for extremely to very preterm stages, the

event rates of DNV were numerically lower in ASD compared to non-ASD individuals, even though

this difference was not statistically significant (Additional file 1: Figure S8).

We also investigated the rates of inherited variants, focusing on those affecting NDD genes and

protein-coding regions. From 4,974 individuals with phenotype information, we did not observe

statistically significant differences between ASD-preterm and ASD-term nor between ASD-preterm

and non-ASD-preterm, although ASD-preterm tend to have a numerically higher rate of rare

inherited variants (Figure 3C, 3F, Additional file 1: Figure S6E, S6F).

Figure 3. Association between genetic variant burden and subgroups with varying preterm birth and ASD status in the SPARK cohort. In ASD individuals, event rates of de novo variants (DNV) identified through genome sequencing (A) and exome sequencing (B), and inherited variants on dominant and recessive NDD genes identified through genome sequencing (C) were calculated. In preterm individuals, event rates of de novo variants identified through genome sequencing (D) and exome sequencing (E), and inherited variants in dominant and recessive NDD genes identified through genome sequencing (F) were calculated. Data are presented as mean values ± standard errors as error bars. The GEE model with Poisson family and sex covariate was used to compute the p-value to assess the differences in DNV count between groups.

To further test whether the multimorbidity would be a modifying factor for the differences in the

DNV burden, we computed GEE models (Additional file 1: Table S10) and found that multimorbidity

is positively correlated with GS LOF (p-value=0.037), GS LOF on NDD genes (p-value=5.3×10^{-06}) and all

types of ES DNV burden (p-value=1.1×10^{-05}, 1.9×10^{-09}, 6.6×10^{-14} and <2.2×10^{-6} for DNV, LOF, DNV on

NDD genes and LOF on NDD genes respectively) across all individuals. Stratified by preterm and ASD

status, we observed this positive correlation pattern in ASD-term group for ES DNV (p-value=0.009),

ES DNV on NDD genes (p-value=0.013) and LOF on NDD genes (p-value=0.004), as well as in ASD-

preterm group for ES LOF on NDD genes (p-value=0.013) (Additional file 1: Figure S9). However,

except for GS DNV on NDD genes, there is no interaction between DNV burden and multimorbidity

performing on ASD or preterm outcomes.

ASD Polygenic risk score and association with preterm status

We calculated ASD PRS for individuals in the SPARK cohort using the most comprehensive GWAS on

ASD as source data [10]. There was no significant difference in the distribution of PRS between the

ASD-preterm and ASD-term groups nor between ASD-preterm and non-ASD-preterm (Figure 4A). As

expected, ASD individuals had higher PRS compared to non-ASD individuals in the whole cohort

displaying the usability of the PRS (2-sided Wilcoxon rank sum test, p-value=6.7×10^{-13}) (Figure 4A).

Additionally, after adjusting for sex and population ancestry (as indicated by principal components

[PC]) in a GEE logistic model, we confirmed that there was no independent association between

preterm birth and PRS (in ASD population), or between ASD diagnosis and PRS (in preterm

population). The statistically non-significant association between preterm birth and PRS (in ASD

population) was replicated in the SSC cohort (Additional file 1: Figure S10). Furthermore, we

computed a full GEE logistic model for ASD diagnosis within European populations, showing that

male sex, preterm birth, and higher PRS were all positively associated with ASD diagnosis (p-

value<2×10^{-16}, <2×10^{-16} and 2.2×10^{-12}, respectively) (Figure 4B). In this model, the predicted

probability of an ASD diagnosis was almost 90% for preterm-born males, with the highest PRS (Figure

4C). Then, we included the interaction between preterm status and PRS in the full GEE logistic model,

observing a significant association between this interaction and ASD diagnosis (p = 0.017).

Figure 4. The association of polygenic risk score (PRS) with delivery term and ASD condition in
SPARK cohort. A. The distribution of standardized PRS in groups with different delivery terms and
ASD diagnosis. Statistical significance was assessed using the 2-sided Wilcoxon rank sum test with the
p-value marked in the plots as 0-0.001*** or NS (statistically non-significant difference). B.
Coefficient plot for the GEE logistic model [ASD(y/n) ~ sex(m/f) + Preterm status(y/n) + Standardized
PRS], displaying the estimated coefficients for each variable. Positive coefficients suggest an increase
in the likelihood of ASD associated with the variable, while negative coefficients indicate a
decrease. Error bars represent 95% CI. C. Visualized effect plot of GEE model, which shows average
predicted probabilities of ASD diagnosis for specific levels of variables, with color region around the
line showing 95% CI.

Predictive model for ASD within preterm births

Lastly, we investigated the potential of ML models to identify those preterm infants with a high

likelihood of ASD from information present at birth by combining clinical and available genetic data.

The model was developed and tested using a study population with preterm individuals classified

into ASD (n=279) and non-ASD (n=150). For features used in prediction model, we also considered

Combined Annotation Dependent Depletion (CADD) scores which assess the potential impact (i.e.

deleterious or benign) of genetic variants on the function of genes and available for most of the

DNVs. We applied Recursive Feature Elimination (RFE) and a correlation threshold of 0.7 to select 13

features, including clinical features (sex, condition of birth complications, gestational age, insufficient

oxygen at birth) and genomic features (number of several types of variants, CADD scores and

standardized ASD-PRS) (Additional file 1: Figure S11A, Table S6). We used three algorithms to train

the models (Table 2), of which the XGBoost model exhibited the highest area under the receiver

operating characteristic curve (AUROC), at 0.65. The model accurately identified 69% (95% CI 0.644-

0.733) ASD diagnosis in the preterm, with a sensitivity of 0.81, specificity of 0.47, and F1-score of

0.77.

The first three XGBoost models within the 10-fold training (Additional file 1: Figure S11B) were

selected to visualize feature effects for this best-performing model. The feature importance varied

slightly across the training XGBoost models with sex, PRS, and CADD score being the most important

features (Additional file 1: Figure S11C, S11E, S11G). Using SHAP values to characterize the impact of

each feature on the model's output for specific individuals, we found that sex had the highest

significant impact on the model's predictions, whereas being male had a positive impact on the

model's prediction. Furthermore, we demonstrate that lower gestational age, more autosomal

exonic DNVs, more dominant inherited variants, more LOF variants, the presence of birth

complications, and insufficient oxygen at birth drove the model towards ASD prediction result

(Additional file 1: Figure S11D, S11F, S11H).

Table 2. Performance metrics of machine learning model used to predict ASD diagnosis in preterm
individuals.

Algorithm	Accuracy	95% CI	AUC	Sensitivity	Specificity	F1-score
XGBoost	0.69	(0.64, 0.73)	0.65	0.81	0.47	0.77
Random forest	0.67	(0.63, 0.72)	0.63	0.86	0.33	0.77
SVM	0.70	(0.66, 0.75)	0.62	0.84	0.46	0.79

Discussion

Here, we conducted a comprehensive analysis of phenotypic differences using larger cohorts, as well as genotypic differences which have been explored in only a few studies among preterm and term-birth ASD individuals. We conclude that preterm-born ASD individuals have more diagnoses across different categories and a number of co-occurring diagnoses but similar genetic landscapes when investigating sequence-level rare DNVs and inherited variants as well as a polygenic load for ASD compared with ASD-term. Our analysis of preterm individuals with and without ASD showed similar results for the phenotype comparisons but inconsistent findings for the genetic burden. The largest de novo dataset derived from ES showed that the ASD-preterm had a higher exonic DNV event rate than the non-ASD-preterm; however, we did not validate this finding in the de novo dataset from GS. Additionally, the male with preterm status and higher polygenic load faces a higher likelihood of ASD when considering these features together. Furthermore, our ML model demonstrated potential for predicting ASD diagnosis in preterm children by integrating phenotype and genetic information. Our results provide evidence that genetic factors play a role in emerging ASD in preterm birth, but the environmental stressor of being preterm most likely contributes to the severity and multimorbidity.

Previous research has reported numerous but inconsistent findings regarding phenotypic disparities between ASD preterm and term individuals [19,21], while limited research has focused on

investigating the genetic link of ASD in prematurity. Unlike most phenotypic comparisons that

concentrate on specific diagnostic outcomes [20,21], we first grouped the various conditions into

nine broader diagnostic categories. Our results indicate that children with both preterm birth and

ASD exhibit a higher prevalence of diagnoses within these categories and a higher rate of

multimorbidity across different diagnostic categories. Previous studies have found that both preterm

birth and ASD are associated with adverse symptoms. For instance, preterm infants are

independently inherently prone to multimorbidity and severe health complications affecting

multiple organs and systems [16,51,52], such as visual and auditory impairments [53], epilepsy [54],

ADHD [17], and other psychiatric disorders [18]. This supports the hypothesis that environmental

liability factors like preterm may influence some of the heterogeneity and higher comorbidity rates

observed in ASD [55].

After stratifying preterm based on gestational age, we observed that those born with lower

gestational age tend to have more severe outcomes, which is in line with the dose-effect reported in

prematurity, where the likelihood of developmental issues increases with decreasing gestational age

[52]. This effect is also reflected in the potentially increasing complexity of multimorbidity among

groups with lower gestational age [16]. Additionally, we showed significantly more severe symptom

levels, as measured by different standardized questionnaires and cognitive tests, in ASD-preterm,

consistent with previous studies as well as general research comparing preterm and term birth

[17,56–58]. It is important to note that with large sample sizes, even very small differences can

become statistically significant. Therefore, the results of the quantitative measures should be

interpreted with caution.

In idiopathic ASD, heritability is estimated to be approximately 80% [6], but in preterm born,

environmental factors account for 60% of the variation in gestational age [59]. Our findings suggest

that genetic factors underly, at least partly, the ASD diagnosis even in preterm but that the complex

552 phenotypic presentation, including multimorbidity, could be due to the environmental stressor of

553 being preterm. Specifically, we did not observe significant differences in DNV numbers between

554 preterm and term ASD individuals. We did observe suggestive evidence that DNV burden could be

555 higher in ASD-preterm compared with non-ASD-preterm, but the finding was inconsistent, which

556 could be due to sample size overall and within each gestational age sub-group. After stratifying by

557 preterm stages, we observed higher point estimates for DNV event rates in ASD compared to non-

558 ASD within the moderate to late preterm birth, while lower point estimates in ASD compared to

559 non-ASD within extremely to very preterm birth, but most of them did not reach statistical

560 significance. If proven statistically significant in a future study, one can speculate that this may be

561 indicative of distinct underlying genetic mechanisms for ASD across different preterm sub-groups.

562 Limited research indicated a higher DNV burden in overall preterm newborn genomes and primarily

563 in genes related to embryonic brain development; however, the study did not consider ASD or

564 another behavioral diagnosis in preterm infants [22]. The increased DNV burden could be thus due

565 to the higher prevalence of ASD within the preterm infant group as similar findings are repeatedly

566 shown for ASD [60].

568 Although GWAS studies of prematurity have identified variations in maternal and fetal genes

569 separately [61,62], few have examined the impact of rare inherited variants. Our study did not find a

570 difference in the burden of rare inherited variants between ASD-preterm and ASD-term individuals.

571 This can be partially explained by the fact that the maternal genome influences prematurity more

572 than the fetal genome [14]. Although we did not find an overall association between ASD PRS and

573 prematurity, we show intriguing findings that those with the highest PRS could have a higher

574 likelihood of ASD, especially in preterm infants and boys. Even after including the interaction

575 between preterm status and PRS, these features maintained a significant association with ASD

576 likelihood, and the interaction itself was significantly associated with ASD diagnosis. Again, these

577 findings need validation, especially as a prior study by Cullen et al. found no evidence of an

interaction effect between ASD polygenic score and gestational age at birth on cognition [15].

However, it is important to note that the cognitive difficulty they measured is only one of the

outcomes that do not imply an ASD diagnosis, and the model they used also included socio-

economic status as a covariate.

Variants at *AGTR2* and *ADCY5* genes were identified as associated with gestational duration and

preterm birth in the GWAS study of Zhang et al [63]. Notably, these two genes are also known as

ASD-associated genes [38]. This overlap suggests that certain genetic factors may influence both

preterm birth and neurodevelopment. Given that our study subjects include individuals with either

preterm or ASD conditions, some of these shared genetic factors may be overlooked. In the future,

the understanding of the role of these genes in both preterm birth and ASD may reveal mechanisms

by which genetic susceptibility to preterm birth contributes to the increased likelihood of ASD and

other NDDs observed in preterm children.

In addition to genetic factors, widespread alterations in brain development associated with preterm

infants may contribute to the increase in ASD likelihood. Previous studies have indicated that

reduced structural brain asymmetry and poor brain development during neonatal life may increase

the liability of ASD in preterm infants [64,65]. Even in preterm children exhibiting similar ASD traits

during childhood, distinct etiological trajectories have been observed involving variations in neonatal

cerebellar volume and developmental delay [66].

Not all preterm infants develop ASD [67]. but we demonstrate that when genetic factors are

combined with the environmental risk of preterm birth, preterm children face an elevated likelihood

of ASD diagnosis. Recognizing the limitations of traditional statistical models in capturing nonlinear

interactions between features, we developed an ML model to predict ASD diagnosis in preterm

children at birth. Unlike previous ASD prediction models that rely on developmental trajectories or

typical characteristics collected as children grow [25,29,68], our ML model utilized only information

available at birth, integrating phenotype and genetic information. Moreover, most previous models

are based on the general population [25,68], limiting their applicability to preterm infants. However,

it is necessary to build prediction models tailored specifically for preterm infants due to the

heterogeneity of ASD phenotypes [1], and preterm ASD children may exhibit specific phenotypes

compared to term ASD children [18]. Although our ML model did not achieve significantly higher

performance, achieving 69% accuracy with a small sample size and few features demonstrates the

feasibility and efficacy of integrating phenotype and genetic information for ASD prediction. There is

still substantial room for improvement in model performance. Increasing the sample size would

provide the model with more learning opportunities and could enhance prediction accuracy.

Additionally, adding more features associated with preterm birth and ASD would benefit the

prediction, such as maternal age, prenatal exposure, and fetal birth weight. Other features like

intubation in the delivery room, family language, parental education, other treatment, Infection, and

ventilation have also been found to have predictive ability for cognitive outcomes in very preterm

infants [29]. It is important to note that we cannot identify the causal relationships between features

selected by the model and ASD diagnosis. Still, we suggest that these features could potentially

enhance prediction models in the future.

Our study has several limitations. Firstly, the cohorts we used are specifically focused on ASD, and

the control group without ASD were still siblings and parents of ASD probands, potentially

underestimating genetic differences between the groups. Given the high heritability estimation in

ASD, siblings with a closer relationship with ASD have a higher relative risk ratio for ASD [4]. We

cannot eliminate these potential genetic influences, which may introduce biases in results and affect

the prediction ability of the ML model. Secondly, we did not stratify analyses by sex due to the

limited sample size, potentially overlooking sex-specific differences in ASD phenotypes and variant

event rates. Thirdly, we focused here only on the sequence level variation; thus, the next step would

be to include more types of genetic variations. Finally, our exploration of genetic factors primarily

focused on average population-level associations and NDD genes, potentially overlooking genetic

effects beyond the currently known ASD-associated genes and variants that may contribute to the

elevated likelihood of ASD in preterm children. Previous studies have pointed out the genetic

association between preterm and ASD, such as common genetic variants linking abnormalities in the

gut-brain axis with both conditions [69]. We believe that combining genetic features and more

detailed phenotypic information will help to explain further why some preterm children have ASD

while others do not.

Conclusion

In conclusion, we demonstrate that ASD genetic liability is similar in ASD-term and ASD-preterm,

suggesting that even within preterm, genetic factors play an important role in etiology. Our study did

not find evidence of a link between genetic factors and preterm birth in ASD. However, our findings

suggest that preterm birth would exacerbate the severity of outcomes in ASD individuals, and this

difference may be driven more by environmental factors. As we observed some differences in the

rate of ES DNV in preterm individuals compared between ASD and non-ASD, we only suggest that

genetic factors may increase the likelihood of a preterm child getting an ASD diagnosis and the

diagnosis is not modified by the interaction between multimorbidity and DNV burden. Through the

development of our ML model, we demonstrate that integrating phenotype and genetic information

is feasible and holds promise for the early prediction of ASD in preterm children at birth. Our study

provides insights into the phenotypic characteristics of ASD preterm individuals. We suggest that

health screening for preterm birth infants should incorporate the collection of genetic data, as it

better supports early clinical identification of ASD and can aid in the guidance of early intervention

strategies.

List of abbreviations

ASD: Autism Spectrum Disorder

SPARK: Simons Foundation Powering Autism Research for Knowledge

SSC: Simons Simplex Collection

GS: Genome sequencing

ES: Exome sequencing

GEE: Generalized Estimating Equations

PRS: Polygenic Risk Score

DNV: De Novo Variants

GWAS: Genome-Wide Association Studies

NDD genes: Neurodevelopmental Disorders-Related Genes

ML: Machine Learning

CBCL: Child Behavior Checklist

DCDQ: Developmental Coordination Disorder Questionnaire

RBS-R: Repetitive Behavior Scale-Revised

SCQ: Social Communication Questionnaire

Fsiq: Full-Scale Intelligence Quotient

AB: Allele Balance

LOF: Loss-of-Function

CADD: Combined Annotation Dependent Depletion

PCA: Principal Component Analysis

PC: Principal Components

CI: Confidence Interval

RFE: Recursive Feature Elimination

XGBoost: Extreme Gradient Boosting

RF: Random Forest

SVM: Linear Support Vector Machine

AUROC: Area Under the Receiver Operating Characteristic Curve

SHAP: SHapley Additive exPlanations

GA: Gestational Age at Birth

OR: Odds Ratio

FDR: False Discovery Rate

Additional files

691   Additional file 1: Supplementary Figures S1–S11 and Supplementary Tables S1–S10. (PDF 3686 kb)

Declarations

Ethics approval and consent to participate: Ethical approval for the data collection and informed

consent were obtained from the participants within the SPARK and SSC projects. The Swedish Ethical

Committee approved this study and data analysis in Sweden (dnr 2020-00400).

Consent for publication: Not applicable.

Availability of data and materials: The data that support the findings of this study are available from

the Simons Foundation Autism Research Initiative (SFARI, https://www.sfari.org/resource/sfaribase)

but restrictions apply to the availability of these data, which were used under license for the current

study, and so are not publicly available. Data are however available from the authors upon

reasonable request and with permission of SFARI. The R scripts used to perform the main analysis

reported in this manuscript are available on GitHub (https://github.com/Tammimies-

Lab/AutismPreterm_Zhang).

Competing interests: The authors declare that they have no competing interests.

Funding: This work was supported by grants from the Swedish Foundation for Strategic Research

(FFL18-0104), the Swedish Research Council (2017-01660_VR, 2017-03043_VR, 2023-02111_VR ,

2023-02451_VR), The Swedish Brain Foundation (FO2021-0073 and F02023-0186), Strategic

Research Area in Neuroscience at Karolinska Institutet (StratNeuro), the China Scholarship Council

(CSC, Zhang), the Sällskapet Barnavård (SBV, Zhang). Furthermore, research reported in this

publication was supported by the Eunice Kennedy Shriver National Institute of Child Health & Human

Development of the National Institutes of Health under Award Number R01HD113669 (NIH, Sandin).

The content is solely the responsibility of the authors and does not necessarily represent the official

views of the National Institutes of Health.

Authors' contributions: Y.Z. and K.T. designed the study and planned the analyses. Y.Z. performed the

analyses. Y.A. provided support for the analysis. S.S., U.Å, and K.T. provided supervision and support

for the analysis. Y.Z. wrote the first draft with feedback from K.T. All authors provided critical

feedback and helped shape the research, analysis, and the final manuscript.

Acknowledgements: We thank all the participants of SPARK and SSC cohorts and Simons Foundation

for access of the data. The computations were performed using resources provided by the National

Academic Infrastructure for Supercomputing in Sweden (NAISS) through Uppsala Multidisciplinary

Center for Advanced Computational Science (UPPMAX).

Reference

1. Rosen NE, Lord C, Volkmar FR. The Diagnosis of Autism: From Kanner to DSM-III to DSM-5 and

Beyond. J Autism Dev Disord. 2021;51:4253–70.

2. Lord C, Brugha TS, Charman T, Cusack J, Dumas G, Frazier T, et al. Autism spectrum disorder. Nat

Rev Dis Primers. 2020;6:5.

3. Carlsson T, Molander F, Taylor MJ, Jonsson U, Bölte S. Early environmental risk factors for

neurodevelopmental disorders – a systematic review of twin and sibling studies. Dev Psychopathol.

2021;33:1448–95.

4. Havdahl A, Niarchou M, Starnawska A, Uddin M, van der Merwe C, Warrier V. Genetic

contributions to autism spectrum disorder. Psychol Med. 2021;51:2260–73.

5. Ruzzo EK, Pérez-Cano L, Jung J-Y, Wang L-K, Kashef-Haghighi D, Hartl C, et al. Inherited and De Novo

Genetic Risk for Autism Impacts Shared Networks. Cell. 2019;178:850-866.e26.

6. Bai D, Yip BHK, Windham GC, Sourander A, Francis R, Yoffe R, et al. Association of Genetic and

Environmental Factors With Autism in a 5-Country Cohort. JAMA Psychiatry. 2019;76:1035.

7. Iossifov I, O'Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D, et al. The contribution of de novo

coding mutations to autism spectrum disorder. Nature. 2014;515:216–21.

8. Zhou X, Feliciano P, Shu C, Wang T, Astrovskaya I, Hall JB, et al. Integrating de novo and inherited

variants in 42,607 autism cases identifies mutations in new moderate-risk genes. Nat Genet.

2022;54:1305–19.

9. Wilfert AB, Turner TN, Murali SC, Hsieh P, Sulovari A, Wang T, et al. Recent ultra-rare inherited

variants implicate new autism candidate risk genes. Nat Genet. 2021;53:1125–34.

10. Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, et al. Identification of common

genetic risk variants for autism spectrum disorder. Nat Genet. 2019;51:431–44.

11. Loughnan RJ, Palmer CE, Makowski C, Thompson WK, Barch DM, Jernigan TL, et al. Unique

prediction of developmental psychopathology from genetic and familial risk. Child Psychology

Psychiatry. 2022;63:1631–43.

12. Crump C, Sundquist J, Sundquist K. Preterm or Early Term Birth and Risk of Autism. Pediatrics.

2021;148:e2020032300.

13. Persson M, Opdahl S, Risnes K, Gross R, Kajantie E, Reichenberg A, et al. Gestational age and the

risk of autism spectrum disorder in Sweden, Finland, and Norway: A cohort study. Fassett MJ, editor.

PLoS Med. 2020;17:e1003207.

14. Svensson AC, Sandin S, Cnattingius S, Reilly M, Pawitan Y, Hultman CM, et al. Maternal Effects for

Preterm Birth: A Genetic Epidemiologic Study of 630,000 Families. American Journal of Epidemiology.

2009;170:1365–72.

15. Cullen H, Selzam S, Dimitrakopoulou K, Plomin R, Edwards AD. Greater genetic risk for adult

psychiatric diseases increases vulnerability to adverse outcome after preterm birth. Sci Rep.

2021;11:11443.

16. Heikkilä K, Metsälä J, Pulakka A, Nilsen SM, Kivimäki M, Risnes K, et al. Preterm birth and the risk

of multimorbidity in adolescence: a multiregister-based cohort study. The Lancet Public Health.

2023;8:e680–90.

17. Allotey J, Zamora J, Cheong-See F, Kalidindi M, Arroyo-Manzano D, Asztalos E, et al. Cognitive,

motor, behavioural and academic performances of children born preterm: a meta-analysis and

systematic review involving 64 061 children. BJOG. 2018;125:16–25.

18. Johnson S, Marlow N. Preterm Birth and Childhood Psychiatric Disorders. Pediatric Research.

2011;69:11R-18R.

19. Joseph RM, Lai ER, Bishop S, Yi J, Bauman ML, Frazier JA, et al. Comparing autism phenotypes in

children born extremely preterm and born at term. Autism Research. 2023;16:653–66.

20. Leoni M, Vanes LD, Hadaya L, Kanel D, Dazzan P, Simonoff E, et al. Exploring cognitive, behavioral

and autistic trait network topology in very preterm and term-born children. Front Psychol.

2023;14:1119196.

21. Luu J, Jellett R, Yaari M, Gilbert M, Barbaro J. A Comparison of Children Born Preterm and Full-

Term on the Autism Spectrum in a Prospective Community Sample. Front Neurol. 2020;11:597505.

22. Li J, Oehlert J, Snyder M, Stevenson DK, Shaw GM. Fetal de novo mutations and preterm birth.

Williams SM, editor. PLoS Genet. 2017;13:e1006689.

23. Wong HS, Wadon M, Evans A, Kirov G, Modi N, O'Donovan MC, et al. Contribution of de novo and

inherited rare CNVs to very preterm birth. J Med Genet. 2020;57:552–7.

24. Everett SS, Bomback M, Sahni R, Wapner RJ, Tolia VN, Clark RH, et al. Prevalence and Clinical

Significance of Commonly Diagnosed Genetic Disorders in Preterm Infants. Preprint at

http://medrxiv.org/lookup/doi/10.1101/2023.07.14.23292662 (2023)

25. Chen J, Engelhard M, Henao R, Berchuck S, Eichner B, Perrin EM, et al. Enhancing early autism

prediction based on electronic records using clinical narratives. Journal of Biomedical Informatics.

2023;144:104390.

26. Rajagopalan SS, Zhang Y, Yahia A, Tammimies K. Machine Learning Prediction of Autism Spectrum

Disorder From a Minimal Set of Medical and Background Information. JAMA Netw Open.

2024;7:e2429229.

27. Asif M, Martiniano HFMC, Marques AR, Santos JX, Vilela J, Rasga C, et al. Identification of

biological mechanisms underlying a multidimensional ASD phenotype using machine learning. Transl

Psychiatry. 2020;10:43.

28. Li D, Choque Olsson N, Becker M, Arora A, Jiao H, Norgren N, et al. Rare variants in the outcome

of social skills group training for autism. Autism Res. 2022;15:434–46.

29. Bowe AK, Lightbody G, Staines A, Murray DM, Norman M. Prediction of 2-Year Cognitive

Outcomes in Very Preterm Infants Using Machine Learning Methods. JAMA Netw Open.

2023;6:e2349111.

30. Feliciano P, Daniels AM, Green Snyder L, Beaumont A, Camba A, Esler A, et al. SPARK: A US Cohort

of 50,000 Families to Accelerate Autism Research. Neuron. 2018;97:488–93.

31. Fischbach GD, Lord C. The Simons Simplex Collection: A Resource for Identification of Autism

Genetic Risk Factors. Neuron. 2010;68:192–5.

32. Ng JK, Vats P, Fritz-Waters E, Sarkar S, Sams EI, Padhi EM, et al. de novo variant calling identifies

cancer mutation signatures in the 1000 Genomes Project. Human Mutation. 2022;43:1979–93.

33. Weiner DJ, Wigdor EM, Ripke S, Walters RK, Kosmicki JA, Grove J, et al. Polygenic transmission

disequilibrium confirms that common and rare variation act additively to create risk for autism

spectrum disorders. Nature genetics. 2017;49:978–85.

34. Pedersen BS, Brown JM, Dashnow H, Wallace AD, Velinder M, Tristani-Firouzi M, et al. Effective

variant filtering and expected candidate variant yield in studies of rare human disease. npj Genom

Med. 2021;6:60.

35. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome

Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data.

Genome Res. 2010;20:1297–303.

36. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-

throughput sequencing data. Nucleic Acids Research. 2010;38:e164–e164.

37. Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, Wang L, et al. A program for annotating and

predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila

melanogaster strain w [1118] ; iso-2; iso-3. Fly. 2012;6:80–92.

38. Abrahams BS, Arking DE, Campbell DB, Mefford HC, Morrow EM, Weiss LA, et al. SFARI Gene 2.0:

a community-driven knowledgebase for the autism spectrum disorders (ASDs). Molecular Autism.

2013;4:36.

39. Martin AR, Williams E, Foulger RE, Leigh S, Daugherty LC, Niblock O, et al. PanelApp crowdsources

expert knowledge to establish consensus diagnostic gene panels. Nat Genet. 2019;51:1560–5.

40. Danecek P, Auton A, Abecasis G, Albers CA, Banks E, DePristo MA, et al. The variant call format

and VCFtools. Bioinformatics. 2011;27:2156–8.

41. Kochinke K, Zweier C, Nijhof B, Fenckova M, Cizek P, Honti F, et al. Systematic Phenomics Analysis

Deconvolutes Genes Mutated in Intellectual Disability into Biologically Coherent Modules. The

American Journal of Human Genetics. 2016;98:149–64.

42. Firth HV, Richards SM, Bevan AP, Clayton S, Corpas M, Rajan D, et al. DECIPHER: Database of

Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources. The American Journal

of Human Genetics. 2009;84:524–33.

43. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to

the challenge of larger and richer datasets. GigaSci. 2015;4:7.

44. Hinrichs AS. The UCSC Genome Browser Database: update 2006. Nucleic Acids Research.

2006;34:D590–8.

45. Ge T, Chen C-Y, Ni Y, Feng Y-CA, Smoller JW. Polygenic prediction via Bayesian regression and

continuous shrinkage priors. Nat Commun. 2019;10:1776.

46. Halekoh U, Højsgaard S, Yan J. The R Package geepack for Generalized Estimating Equations. J Stat

Soft. 2006;15:2.

47. Lüdecke D. ggeffects: Tidy Data Frames of Marginal Effects from Regression Models. Journal of

Open Source Software. 2018;3:772.

48. Gregorutti B, Michel B, Saint-Pierre P. Correlation and variable importance in random forests. Stat

Comput. 2017;27:659–78.

49. Kuhn M. Building Predictive Models in R Using the caret Package. J Stat Soft . 2008;28:5.

50. Liu Y, Just A. SHAPforxgboost: SHAP Plots for "XGBoost". R package version 0.1.3.; 2020.

https://github.com/liuyanguu/SHAPforxgboost/

51. Heikkilä K, Pulakka A, Metsälä J, Alenius S, Hovi P, Gissler M, et al. Preterm birth and the risk of

chronic disease multimorbidity in adolescence and early adulthood: A population-based cohort

study. Jacobsen R, editor. PLoS ONE. 2021;16:e0261952.

52. Johnson S, Marlow N. Growing up after extremely preterm birth: Lifespan mental health

outcomes. Seminars in Fetal and Neonatal Medicine. 2014;19:97–104.

53. Hirvonen M, Ojala R, Korhonen P, Haataja P, Eriksson K, Gissler M, et al. Visual and Hearing

Impairments After Preterm Birth. Pediatrics. 2018;142:e20173888.

54. Li W, Peng A, Deng S, Lai W, Qiu X, Zhang L, et al. Do premature and postterm birth increase the

risk of epilepsy? An updated meta-analysis. Epilepsy & Behavior. 2019;97:83–91.

55. Khachadourian V, Mahjani B, Sandin S, Kolevzon A, Buxbaum JD, Reichenberg A, et al.

Comorbidities in autism spectrum disorder and their etiologies. Transl Psychiatry. 2023;13:71.

56. Johnson S, Hollis C, Kochhar P, Hennessy E, Wolke D, Marlow N. Autism Spectrum Disorders in

Extremely Preterm Children. The Journal of Pediatrics. 2010;156:525-531.e2.

57. Schieve LA, Baio J, Rice CE, Durkin M, Kirby RS, Drews-Botsch C, et al. Risk for cognitive deficit in a

population-based sample of U.S. children with autism spectrum disorders: Variation by perinatal

health factors. Disability and Health Journal. 2010;3:202–12.

58. Zhu JL, Olsen J, Olesen AW. Risk for Developmental Coordination Disorder Correlates with

Gestational Age at Birth. Paediatric Perinatal Epid. 2012;26:572–7.

59. York TP, Eaves LJ, Lichtenstein P, Neale MC, Svensson A, Latendresse S, et al. Fetal and Maternal

Genes' Influence on Gestational Age in a Quantitative Genetic Analysis of 244,000 Swedish Births.

American Journal of Epidemiology. 2013;178:543–50.

60. Li C, Fleck JS, Martins-Costa C, Burkard TR, Themann J, Stuempflen M, et al. Single-cell brain

organoid screening identifies developmental defects in autism. Nature. 2023;621:373–80.

61. Solé-Navais P, Flatley C, Steinthorsdottir V, Vaudel M, Juodakis J, Chen J, et al. Genetic effects on

the timing of parturition and links to fetal birth weight. Nat Genet. 2023;55:559–67.

62. Liu X, Helenius D, Skotte L, Beaumont RN, Wielscher M, Geller F, et al. Variants in the fetal

genome near pro-inflammatory cytokine genes on 2q13 associate with gestational duration. Nat

Commun. 2019;10:3927.

874 63. Zhang G, Feenstra B, Bacelis J, Liu X, Muglia LM, Juodakis J, et al. Genetic Associations with

875 Gestational Duration and Spontaneous Preterm Birth. N Engl J Med. 2017;377:1156–67.

876 64. Eklöf E, Mårtensson GE, Ådén U, Padilla N. Reduced structural brain asymmetry during neonatal

877 life is potentially related to autism spectrum disorders in children born extremely preterm. Autism

878 Research. 2019;12:1334–43.

879 65. Padilla N, Eklöf E, Mårtensson GE, Bölte S, Lagercrantz H, Ådén U. Poor Brain Growth in Extremely

880 Preterm Neonates Long Before the Onset of Autism Spectrum Disorder Symptoms. Cereb Cortex.

881 2015;bhv300.

882 66. Hadaya L, Vanes L, Karolis V, Kanel D, Leoni M, Happé F, et al. Distinct Neurodevelopmental

883 Trajectories in Groups of Very Preterm Children Screening Positively for Autism Spectrum Conditions.

884 J Autism Dev Disord. 2024;54:256–69.

885 67. Hee Chung E, Chou J, Brown KA. Neurodevelopmental outcomes of preterm infants: a recent

886 literature review. Transl Pediatr. 2020;9:S3–8.

887 68. Amit G, Bilu Y, Sudry T, Avgil Tsadok M, Zimmerman DR, Baruch R, et al. Early Prediction of

888 Autistic Spectrum Disorder Using Developmental Surveillance Data. JAMA Netw Open.

889 2024;7:e2351052.

890 69. Sajdel-Sulkowska EM, Makowska-Zubrycka M, Czarzasta K, Kasarello K, Aggarwal V, Bialy M, et al.

891 Common Genetic Variants Link the Abnormalities in the Gut-Brain Axis in Prematurity and Autism.

892 Cerebellum. 2019;18:255–65.